Top Story

Clustering prevalent among injection drug users with HCV in Vancouver

October 30, 2014

One-third of people who inject drugs with hepatitis C virus infection from the Vancouver Injection Drug Users Study were found to be clustered, a phenomenon that is a risk factor for HCV transmission and associated with HCV seroconversion and HIV infection, according to data from a recent study.

“This study characterizes the molecular epidemiology of HCV among a cohort of [people who inject drugs] recruited between 1996 and 2012 in Vancouver, Canada,” the researchers wrote. “These findings could be used to better design and target public health and treatment strategies towards groups at higher risk of HCV transmission among [people who inject drugs].”

figure Meeting News Coverage

HBV prevalent in Ugandan pregnant mothers and increased early childhood transmission

October 29, 2014
PHILADELPHIA — Hepatitis B virus is highly prevalent among the population in northern Uganda, including pregnant mothers aged 20 years or younger, according to…
figure Meeting News CoverageVideo

Marshall discusses the safety, efficacy of a potential combination vaccine for infants

October 28, 2014
PHILADELPHIA — At IDWeek 2014, Gary S. Marshall, MD, chief of pediatric infectious diseases at the University of Louisville School of Medicine, discussed results…
In the Journals

Networking strategy may decrease HCV prevalence among injection drug users

October 28, 2014
In a new study, researchers in Australia found that using a social network-based approach to treating injection drug users with hepatitis C virus infection led to…
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »
Meeting News Coverage Video
figure

Marshall discusses the safety, efficacy of a potential combination vaccine for infants

October 28, 2014
PHILADELPHIA — At IDWeek 2014, Gary S. Marshall, MD, chief of pediatric infectious diseases at the University of…
More »
CME
figure

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »

Filter By:

In the Journals

Clustering prevalent among injection drug users with HCV in Vancouver

October 30, 2014
One-third of people who inject drugs with hepatitis C virus infection from the Vancouver Injection Drug Users Study were found to be clustered, a…
figure Meeting News Coverage

HBV prevalent in Ugandan pregnant mothers and increased early childhood transmission

October 29, 2014
PHILADELPHIA — Hepatitis B virus is highly prevalent among the population in northern Uganda, including pregnant mothers aged 20 years or…
figure Meeting News Coverage Video

Marshall discusses the safety, efficacy of a potential combination vaccine for infants

October 28, 2014
PHILADELPHIA — At IDWeek 2014, Gary S. Marshall, MD, chief of pediatric infectious diseases at the University of Louisville School of…
In the Journals

Networking strategy may decrease HCV prevalence among injection drug users

October 28, 2014
In a new study, researchers in Australia found that using a social network-based approach to treating injection drug users with hepatitis C virus…
In the Journals

High sCD163 predicted mortality in patients with alcoholic hepatitis

October 27, 2014
In a recent study, patients with acute alcoholic hepatitis had higher levels of soluble CD163, which led to increased mortality, compared with…
Meeting News Coverage

Few infants tested for HCV after birth, more perinatal testing needed

October 24, 2014
PHILADELPHIA — Very few infants in Philadelphia were tested for hepatitis C virus infection after birth despite mothers who reported being…
Meeting News Coverage

Safety concerns common reason for hepatitis B vaccine refusal

October 24, 2014
SAN DIEGO — Safety and uncertainty involving the risk for hepatitis B are reasons for barriers to vaccine uptake, according to recent study…
Meeting News Coverage Video

New therapies create 'optimistic time' for HCV, expert says

October 24, 2014
PHILADELPHIA — Stanley Martin Cohen, MD, medical director of hepatology at UH Case Medical Center, Cleveland, Ohio, discusses the high points…

Potential drug decreased viral load in patients with various HCV genotypes

October 23, 2014
Interim results from an ongoing clinical trial revealed that a microRNA therapeutic was well-tolerated and safe for the treatment of hepatitis C…
figure Meeting News Coverage

Decreased hemoglobin levels did not impact SVR rate in patients treated for HCV genotype 1

October 22, 2014
PHILADELPHIA — Decreased hemoglobin levels were well-managed in patients with hepatitis C virus infection receiving a three direct-acting…
More Headlines »